Progress toward development of a hepatitis C vaccine with broad shoulders

Science Translational Medicine

Volumn 3, Issue 94, 2011, Pages

  Ray, Ranjit ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VACCINE; SUBUNIT VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS LIKE PARTICLE VACCINE; HEPATITIS C ANTIBODY; HEPATITIS VACCINE; NEUTRALIZING ANTIBODY;

ADENOVIRUS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; CROSS REACTION; DRUG POTENCY; DRUG TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGENICITY; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMATITIS; VACCINE PRODUCTION; VIRUS NEUTRALIZATION; ARTICLE; BIOSYNTHESIS; IMMUNOLOGY;

ANTIBODIES, NEUTRALIZING; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; VIRAL HEPATITIS VACCINES;

EID: 79961213651     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002772     Document Type: Review

References (18)

1. P. Garrone, A.-C. Fluckiger, P. E. Mangeot, E. Gauthier, P. Dupeyrot-Lacas, J. Mancip, A. Cangialosi, I. Du Chéné, R. LeGrand, I. Mangeot, D. Lavillette, B. Bellier, F.-L Cosset, F. Tangy, D. Klatzmann, C. Dalba, A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 3, 94ra71 (2011).
2. L. M. Lagging, K. Meyer, R. J. Owens, R. Ray, Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J. Virol. 72, 3539-3546 (1998).
3. K. Meyer, A. Beyene, T. L. Bowlin, A. Basu, R. Ray, Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer. J. Virol. 78, 12838-12847 (2004).
4. S. E. Frey, M. Houghton, S. Coates, S. Abrignani, D. Chien, D. Rosa, P. Pileri, R. Ray, A. M. Di Bisceglie, P. Rinella, H. Hill, M. C. Wolff, V. Schultze, J. H. Han, B. Scharschmidt, R. B. Belshe, Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28, 6367-6373 (2010).
5. R. Ray, K. Meyer, A. Banerjee, A. Basu, S. Coates, S. Abrignani, M. Houghton, S. E. Frey, R. B. Belshe, Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J. Infect. Dis. 202, 862-866 (2010).
6. L. M. Lagging, K. Meyer, J. Westin, R. Wejstål, G. Norkrans, M. Lindh, R. Ray, Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients. J. Infect. Dis. 185, 1165-1169 (2002).
7. K. Meyer, A. Basu, C. T. Przysiecki, L. M. Lagging, A. M. Di Bisceglie, A. J. Conley, R. Ray, Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J. Virol. 76, 2150-2158 (2002).
8. A. L. Rothman, C. Morishima, H. L. Bonkovsky, S. J. Polyak, R. Ray, A. M. Di Bisceglie, K. L. Lindsay, P. F. Malet, M. Chang, D. R. Gretch, D. G. Sullivan, A. K. Bhan, E. C. Wright, M. J. Koziel; HALT-C Trial Group, Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 41, 617-625 (2005).
9. A. Beyene, A. Basu, K. Meyer, R. Ray, Infl uence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity. Virology 324, 273-285 (2004).
10. B. Mazumdar, A. Banerjee, K. Meyer, R. Ray, Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology 25 July 2011 (10.1002/hep.24523).
11. K. Saito, M. Ait-Goughoulte, S. M. Truscott, K. Meyer, A. Blazevic, G. Abate, R. B. Ray, D. F. Hoft, R. Ray, Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J. Virol. 82, 3320-3328 (2008).
12. R. Ray, A. Khanna, L. M. Lagging, K. Meyer, Q.-L. Choo, R. Ralston, M. Houghton, P. R. Becherer, Peptide immunogen mimicry of putative E1 glycoprotein-specifi c epitopes in hepatitis C virus. J. Virol. 68, 4420-4426 (1994).
13. J.-C. Meunier, R. S. Russell, V. Goossens, S. Priem, H. Walter, E. Depla, A. Union, K. N. Faulk, J. Bukh, S. U. Emerson, R. H. Purcell, Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82, 966-973 (2008).
14. Z. Stamataki, S. Coates, M. J. Evans, M. Wininger, K. Crawford, C. Dong, Y.-L. Fong, D. Chien, S. Abrignani, P. Balfe, C. M. Rice, J. A. McKeating, M. Houghton, Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 25, 7773-7784 (2007).
15. A. Banerjee, B. Mazumdar, K. Meyer, A. M. Di Bisceglie, R. B. Ray, R. Ray, Transcriptional repression of C4 complement by hepatitis C virus proteins. J. Virol. 85, 4157-4166 (2011).
16. K. Meyer, M. Ait-Goughoulte, Z.-Y. Keck, S. Foung, R. Ray, Antibody-dependent enhancement of hepatitis C virus infection. J. Virol. 82, 2140-2149 (2008).
17. M. Dorner, J. A. Horwitz, J. B. Robbins, W. T. Barry, Q. Feng, K. Mu, C. T. Jones, J. W. Schoggins, M. T. Catanese, D. R. Burton, M. Law, C. M. Rice, A. Ploss, A genetically humanized mouse model for hepatitis C virus infection. Nature 474, 208-211 (2011).
18. Funding: R.R.'s research was supported by a contract (N01-AI-25464) and grants (RO1AI068769 and U54- AI057160) from the National Institutes of Health. Competing interests: The author declares no competing interests.